Similarly Akt specific SH5, also reduces survivin expression along with the significant reduction in other IAPs in chronic myeloid leukemia (CML), lung and prostate cancer [153, 154]. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.